Home > Insider Trading > Filing (0001209191-18-061982)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1169245	Phasebio Pharmaceuticals Inc	PHAS	Pharmaceutical Preparations (2834)	030375697

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1313942	P Jonathan Mow	C/O Phasebio Pharmaceuticals, Inc. 1 Great Valley Parkway, Suite 30 Malvern PA 19355	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-12-07	2,200	$3.88	50,899	No	4	P	Indirect	By the Mow Trust dated April 17, 2008
Common Stock	Acquisiton	2018-12-10	800	$3.85	51,699	No	4	P	Indirect	By the Mow Trust dated April 17, 2008

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By the Mow Trust dated April 17, 2008
No	4	P	Indirect	By the Mow Trust dated April 17, 2008

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $4.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
The reporting person and his wife are joint trustees of the Mow Trust dated April 17, 2008 and share voting and dispositive power for such shares. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $3.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.